MGEN vs. BDSX, SERA, MDXH, XGN, BNR, ENZ, OPGN, BGLC, ACON, and NTRA
Should you be buying Miragen Therapeutics stock or one of its competitors? The main competitors of Miragen Therapeutics include Biodesix (BDSX), Sera Prognostics (SERA), MDxHealth (MDXH), Exagen (XGN), Burning Rock Biotech (BNR), Enzo Biochem (ENZ), OpGen (OPGN), BioNexus Gene Lab (BGLC), Aclarion (ACON), and Natera (NTRA).
Miragen Therapeutics vs.
Miragen Therapeutics (NASDAQ:MGEN) and Biodesix (NASDAQ:BDSX) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, community ranking, institutional ownership, analyst recommendations, risk, media sentiment, dividends, earnings and valuation.
Biodesix has a consensus target price of $3.06, suggesting a potential upside of 246.94%. Given Biodesix's stronger consensus rating and higher probable upside, analysts clearly believe Biodesix is more favorable than Miragen Therapeutics.
Miragen Therapeutics has a beta of 1.66, suggesting that its share price is 66% more volatile than the S&P 500. Comparatively, Biodesix has a beta of 1.06, suggesting that its share price is 6% more volatile than the S&P 500.
Biodesix has a net margin of -66.84% compared to Miragen Therapeutics' net margin of -1,393.50%. Miragen Therapeutics' return on equity of -141.66% beat Biodesix's return on equity.
In the previous week, Biodesix had 1 more articles in the media than Miragen Therapeutics. MarketBeat recorded 1 mentions for Biodesix and 0 mentions for Miragen Therapeutics. Biodesix's average media sentiment score of 0.97 beat Miragen Therapeutics' score of 0.00 indicating that Biodesix is being referred to more favorably in the news media.
Miragen Therapeutics has higher earnings, but lower revenue than Biodesix. Biodesix is trading at a lower price-to-earnings ratio than Miragen Therapeutics, indicating that it is currently the more affordable of the two stocks.
21.0% of Biodesix shares are owned by institutional investors. 1.1% of Miragen Therapeutics shares are owned by company insiders. Comparatively, 69.2% of Biodesix shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
Miragen Therapeutics received 238 more outperform votes than Biodesix when rated by MarketBeat users. However, 74.36% of users gave Biodesix an outperform vote while only 70.45% of users gave Miragen Therapeutics an outperform vote.
Summary
Biodesix beats Miragen Therapeutics on 12 of the 18 factors compared between the two stocks.
Get Miragen Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for MGEN and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Miragen Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:MGEN) was last updated on 2/23/2025 by MarketBeat.com Staff
